Dexmedetomidine is an α2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, and minimal depression of respiratory function. It is potent and highly selective for α2-receptors with an α2:α1 ratio of 1620:1. Hemodynamic effects, which include transient hypertension, bradycardia, and hypotension, result from the drug’s peripheral vasoconstrictive and sympatholytic properties. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsynaptic α2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique aspect that patients remain easily rousable and cooperative. Dexmedetomidine is rapidly distributed and is mainly hepatically metabolized into inactive metabolites by glucuronidation and hydroxylation. A high inter-individual variability in dexmedetomidine pharmacokinetics has been described, especially in the intensive care unit population. In recent years, multiple pharmacokinetic non-compartmental analyses as well as population pharmacokinetic studies have been performed. Body size, hepatic impairment, and presumably plasma albumin and cardiac output have a significant impact on dexmedetomidine pharmacokinetics. Results regarding other covariates remain inconclusive and warrant further research. Although initially approved for intravenous use for up to 24 h in the adult intensive care unit population only, applications of dexmedetomidine in clinical practice have been widened over the past few years. Procedural sedation with dexmedetomidine was additionally approved by the US Food and Drug Administration in 2003 and dexmedetomidine has appeared useful in multiple off-label applications such as pediatric sedation, intranasal or buccal administration, and use as an adjuvant to local analgesia techniques.
US Food and Drug Administration. Precedex label. 1999. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21038lbl.pdf. Accessed 14 Nov 2016.
European Medicines Agency. European Public Assessment Report. 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002268/WC500115631.pdf. Accessed 14 Nov 2016.
Mendeley Ltd. Mendeley reference manager. Amsterdam: Elsevier; 2016.
DrugBank. Dexmedetomidine. 2016. Available from: https://www.drugbank.ca/drugs/DB00633. Accessed 17 Nov 2016.
Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Best Pract Res Clin Anaesthesiol. 2000;14:261–9. CrossRef
Välitalo PA, Ahtola-Sätilä T, Wighton A, et al. Population pharmacokinetics of dexmedetomidine in critically ill patients. Clin Drug Invest. 2013;33:579–87. CrossRef
Rodrigues AD, Roberts EM. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos. 1997;25:651–5. PubMed
Abbott Laboratories. Precedex approval documents. 2001. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.cfm. Accessed 15 Nov 2016.
Tellor BR, Arnold HM, Micek ST, Kollef MH. Occurrence and predictors of dexmedetomidine infusion intolerance and failure. Hosp Pract. 2012;40:186–92. CrossRef
Holliday SF, Kane-Gill SL, Empey PE, et al. Interpatient variability in dexmedetomidine response: a survey of the literature. Sci World J. 2014;2014:805013. CrossRef
Liu H-C, Lian Q-Q, Wu F-F, et al. Population pharmacokinetics of dexmedetomidine after short intravenous infusion in Chinese children. Eur J Drug Metab Pharmacokinet. 2016. doi: 10.1007/s13318-016-0333-6.
Vuyk J, Sitsen E, Reekers M. Intravenous anesthetics. In: Miller RD, Cohen NH, Eriksson LI, et al., editors. Miller’s anesthesia. 8th ed. Amsterdam: Elsevier; 2015. p. 854–9.
Doze V, Chen BX, Li Z, Maze M. Pharmacologic characterization of the receptor mediating the hypnotic action of dexmedetomidine. Acta Vet Scand Suppl. 1989;85:61–4. PubMed
Chen K, Lu Z, Xin YC, et al. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev. 2015;1:CD010269. PubMed
Stiehl SR, Squires JE, Bucuvalas JC, Hemmelgarn TS. Tacrolimus interaction with dexmedetomidine—a case report. Pediatr Transpl. 2016;20:155–7. CrossRef
Harsoor SS, Rani D, Roopa MN, et al. Anesthetic sparing effect of intraoperative lignocaine or dexmedetomidine infusion on sevoflurane during general anesthesia. Middle East J Anaesthesiol. 2015;23:301–7. PubMed
Lundorf LJ, Nedergaard HK, Møller AM. Perioperative dexmedetomidine for acute pain after abdominal surgery in adults. Cochrane Database Syst Rev. 2016;2:CD010358.
Cunningham FE, Baughman VL, Tonkovich L, et al. Pharmacokinetics of dexmedetomidine (DEX) in patients with hepatic failure (HF). Clin Pharmacol Ther. 1999;65:128. CrossRef
European Medicines Agency. Dexdor H-C-2268-II-0003: EPAR, assessment report-variation. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002268/WC500140545.pdf. Accessed 28 Nov 2016.
Chrysostomou C, Schulman SR, Herrera Castellanos M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2014;164(276–82):e1–3.
Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, et al. Effects of dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. Middle East J Anaesthesiol. 2007;19:537–51. PubMed
Mekitarian Filho E, Robinson F, de Carvalho WB, et al. Intranasal dexmedetomidine for sedation for pediatric computed tomography imaging. J Pediatr. 2015;166(1313–15):e1.
Wang S-S, Zhang M-Z, Sun Y, et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. Paediatr Anaesth. 2014;24:275–81. PubMedCrossRef
Yao Y, Qian B, Lin Y, et al. Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial. Paediatr Anaesth. 2015;25:492–8. PubMedCrossRef
Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007;8:25–33. PubMed
Engelhard K, Werner C, Eberspächer E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl- d-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003;96:524–31. PubMedCrossRef
- Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
Maud A. S. Weerink
Michel M. R. F. Struys
Laura N. Hannivoort
Clemens R. M. Barends
Anthony R. Absalom
- Springer International Publishing